Developing an oral dosage form takes more than simply turning an injectable into a tablet or capsule. To do it well, you need the right formulation strategy from the inside out, balancing manufacturability, stability, protection and patient experience. Learn about why more companies are making the move from injectables to tablets or capsules in this blog.
A successful conversion can bring real benefits: better patient convenience and adherence, simpler administration, less burden on healthcare resources, and broader commercial reach. But moving from parenteral to solid oral dose (SOD) isn't a simple “dosage form swap" - it's a fundamental change in how the body encounters the drug, and that change affects everything from API selection and formulation strategy to manufacturing, packaging, clinical bridging and regulatory planning.
This article walks through the key considerations involved in converting an injectable product into a tablet or capsule, with a focus on building a roadmap that reduces technical and regulatory risk.
Before you jump into excipient screening or prototype tablets, start with a simple feasibility question: is this drug molecule biologically and physiochemically suited for oral absorption? Injectables often involve poorly soluble molecules, poorly permeable molecules, highly metabolized molecules, acid- or enzyme-labile compounds or peptides, proteins and other large molecules where oral delivery is intrinsically difficult.
Key API Attributes to Assess Early
| Biopharmaceutics: Solubility across physiological pH, permeability, dissolution rate and impact of bile salts and food. If the molecule has low solubility and/or low permeability, you're probably looking at an enabling strategy rather than a “standard” tablet. | |
|
Dose and potency: Injectables can deliver small volumes very precisely. Oral forms have to fit the dose into a patient-friendly unit:
|
|
| Stability: Injectables may depend on controlled environments such as pH buffers, antioxidants, or refrigerated storage that don't carry over to solids. For oral forms, think about solid-state chemical stability (heat, humidity, oxygen, light), physical stability (polymorph transitions, recrystallization) and compatibility with excipients and processing stress. | |
| Therapeutic window and PK/PD relationship: A wide therapeutic index gives you more room during formulation work. Narrow therapeutic window products need a more cautious path, with tight content uniformity, careful release control, and strong in vitro–in vivo correlation planning. |
This is one of the most common mistakes is treating conversion as a manufacturing exercise instead of a clinical performance exercise. Questions to consider:
When you translate an injectable into an oral form, you often see higher variability, food effects, delayed Tmax, lower Cmax and a need for controlled release (to mimic depot-like profiles). This is where modified release (MR) can become a useful tool, not just for convenience, but for therapeutic equivalence.
There isn't one best approach. The right tablet or capsule design depends on the main barrier you're trying to overcome.
|
Main Challenge |
Potential Formulation Approaches |
|
Solubility |
|
|
Permeability |
|
|
Stability in the GI tract |
|
|
PK shape |
|
A simple way to think about it is: make the drug available, shape the profile, help it survive and make sure it can be scaled consistently.
Developers often lean toward tablets for cost or capsules for speed. But each option comes with technical trade-offs:
|
Dosage form |
Pros |
Cons |
|
Tablets |
|
|
|
Hard capsules |
|
|
Coating is often seen as a final aesthetic step, but in injectable to SOD conversion it often becomes a core functional element. Coatings can support:
From a risk-management point of view, coatings can reduce the need for more complex internal formulation changes by improving protection and robustness at the dosage-form level.
An injectable has much less exposure variability than an oral product. Oral products have to be designed with patient-to-patient differences in mind. Key variables include:
To mitigate variability, prioritize robust dissolution across pH, evaluate biorelevant media, identify precipitation risk early and consider release approaches that reduce dependence on gastric conditions (e.g., enteric delivery to intestine). A successful conversion isn't just about meeting specs on the bench. It has to perform consistently across a diverse patient population too.
Moving from sterile injectable manufacturing to oral solid dose changes the manufacturing reality. Instead of focusing primarily on sterile processing, the development team needs to manage powder behaviour, unit operation performance and a broader set of critical quality attributes from the start.
|
CMC Focus Area |
What to Consider |
|
Powder properties |
Assess flow, cohesion, electrostatics, segregation risk, humidity sensitivity and particle morphology, as these can directly affect blending, compression and overall process consistency. |
|
Unit operations |
Build process understanding around blending uniformity, granulation choice, compression behavior and coating robustness, especially where low-dose actives or sensitive APIs are involved. |
|
Critical Quality Attributes |
Define and control the attributes that matter most for OSD performance, including content uniformity, dissolution profile, mechanical strength, friability, disintegration, coating integrity and moisture content. |
A strong CMC path connects API properties → formulation choices → process design → dissolution/performance → control strategy, helping teams build manufacturability into the product rather than solving it late in development.
Injectables often benefit from controlled atmosphere packaging such as vials or syringes, and sometimes cold chain. Oral products may need to handle longer storage times and wider distribution conditions. Considerations include: moisture, oxygen and/or light protection, child resistance and senior friendliness and global transport and climate zone stability. If the API is moisture sensitive, packaging and coating decisions should be developed together, not one after the other.
Switching from injectable to oral is often treated as a lifecycle strategy, but the evidence requirements can look a lot like those for a new product, especially if exposure changes. You may need:
Regulatory strategy depends heavily on whether you are changing route of administration within the same molecule program (development phase), developing an alternate dosage form for an approved product or seeking equivalence vs establishing a new regimen. The earlier regulatory and clinical teams align with formulation development, the smoother things tend to go.
A successful conversion takes more than choosing a tablet format. It means designing an oral dosage form that performs reliably and can be manufactured consistently at scale. Colorcon can support this journey through:
Getting technical advice early can help developers reduce iteration cycles, improve robustness and create a clearer path from feasibility to commercial manufacture.
Converting from injectable to tablet or capsule can create significant value for patients, healthcare systems, and product lifecycle strategy. But it's a multidisciplinary challenge, and it works best when it's approached with a structured plan: understand the API, define performance targets, choose the right delivery strategy, and design a product that can be manufactured with a clear regulatory path.
With the right partner and the right formulation tools, moving from injectable to oral can go from a strategic goal to a scalable reality. With decades of expertise, technical facilities for development and scale-up, and a range of solutions, including core excipients, film coatings, controlled release systems, and atmosphere-controlled packaging, Colorcon can support you at any stage of your product journey.
Can an injectable drug be converted into a tablet or capsule?
Sometimes, but not always. The drug must be suitable for oral delivery based on factors such as solubility, permeability, stability in the GI tract, dose size and the target pharmacokinetic profile.
Why is bioavailability a major challenge when switching from injectables to oral dosage forms?
Injectables bypass the gastrointestinal tract, while oral dosage forms must survive stomach acid, enzymes, food effects and first-pass metabolism before the drug can reach systemic circulation.
How do you decide whether to use a tablet or capsule?
The choice depends on API properties, dose, development timeline, manufacturability and commercial goals. Capsules are often useful for rapid development, while tablets may be better for scale-up, coating and long-term cost efficiency.
When is modified release or enteric coating needed in an oral formulation?
These approaches may be needed when the drug requires protection from stomach acid, a more controlled release profile, improved tolerability or a PK profile that more closely matches the injectable product.
What studies are typically needed when converting an injectable to an oral product?
Most programs require comparative pharmacokinetic studies, food effect evaluation, stability testing and a clear regulatory strategy to demonstrate that the oral dosage form performs as intended.